Physician profile
John C Kim
NPI 1548310584
$2,121.59
in general payments reported to CMS, 2019-2025
30 companies · $490 in 2025
The $490 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.87 · 2022: $292 · 2023: $496 · 2024: $807 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,792.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $541.06 | 2024-2025 | Onyda Xr |
| Ironshore Pharmaceuticals INC. | $232.66 | 2019-2024 | Jornay Pm |
| Corium, LLC | $165.55 | 2022-2025 | Azstarys |
| Seqirus USA INC | $129.17 | 2023-2025 | Flucelvax, Fluad, Fluad Quadrivalent |
| Abbvie INC. | $102.83 | 2023 | |
| Vertical Pharmaceuticals, LLC | $100.15 | 2023-2024 | Relexxii |
| Glaxosmithkline, LLC. | $88.35 | 2022-2025 | Bexsero, Rotarix, Shingrix |
| Collegium Pharmaceutical, INC. | $84.43 | 2025 | Jornay Pm |
| Bayer Healthcare Pharmaceuticals INC. | $75.36 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $72.85 | 2024-2025 | Zenpep |
| Hologic Sales and Service, LLC | $55.16 | 2023-2025 | Aptima, Thinprep 2000 Processor |
| Supernus Pharmaceuticals, INC. | $50.73 | 2022-2024 | Qelbree |
| Edwards Lifesciences Corporation | $48.57 | 2024 | Sapien 3 Ultra Resilia |
| Sanofi Pasteur INC. | $42.86 | 2022-2024 | |
| Cranial Technologies, INC | $36.95 | 2022-2025 | Doc Band |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.71 | 2022 | |
| Alkermes, INC. | $25.59 | 2024 | Aristada, Lybalvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.33 | 2023 | Tradjenta, Synjardy |
| Ultragenyx Pharmaceutical INC. | $21.24 | 2022 | |
| Sobi, INC | $21.11 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.42 | 2023 | Strensiq |
| Otsuka America Pharmaceutical, INC. | $19.26 | 2023 | Abilify Maintena, Rexulti |
| Vertex Pharmaceuticals Incorporated | $19.07 | 2024 | |
| Avion Pharmaceuticals | $18.89 | 2023 | Methylphenidate Hydrochloride |
| Baxter Healthcare | $18.04 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.43 | 2023 | Livalo |
| Pfizer INC. | $14.57 | 2023 | |
| Exact Sciences Corporation | $14.03 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $13.37 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.85 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.